What does the thrombin time test measure, and why can it be prolonged?

What the Thrombin Time Test Measures and Why It Is Prolonged

The thrombin time (TT) measures the final step of coagulation—the conversion of fibrinogen to fibrin after adding exogenous thrombin to plasma—and is primarily prolonged by direct thrombin inhibitors (especially dabigatran and unfractionated heparin), fibrinogen abnormalities, and fibrin/fibrinogen degradation products.

What the Test Measures

The thrombin time assesses the terminal phase of plasma coagulation by measuring how long it takes for a clot to form after adding a standardized amount of thrombin directly to citrated plasma 1, 2. This bypasses all upstream coagulation factors and isolates the fibrinogen-to-fibrin conversion step.

Primary Causes of Prolongation

Anticoagulant Medications (Most Common in Clinical Practice)

• Dabigatran (direct thrombin inhibitor): TT is highly sensitive to dabigatran 3. A normal TT reliably excludes clinically relevant dabigatran levels, making it an excellent screening tool 4, 5. However, TT is too sensitive for quantification—a prolonged TT cannot distinguish between therapeutic and supratherapeutic levels 6.

• Unfractionated heparin (UFH): TT is highly sensitive to UFH 3. A normal TT can rule out UFH presence.

• Low molecular weight heparins (LMWH): TT is only weakly sensitive to LMWH at therapeutic concentrations (except tinzaparin) 3.

• Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban): These do NOT significantly prolong TT and should not be assessed with this test 3.

Fibrinogen Disorders

• Quantitative deficiencies: Hypofibrinogenemia or afibrinogenemia (congenital or acquired) 7

• Qualitative abnormalities: Dysfibrinogenemia (congenital or acquired) where fibrinogen structure is abnormal 7

• Paradoxically, hyperfibrinogenemia: Elevated fibrinogen levels (>400-500 mg/dL) can prolong TT by interfering with fibrin assembly or binding excess thrombin, though this is typically of minimal clinical significance 8

Fibrin/Fibrinogen Degradation Products (FDPs)

Elevated FDPs from fibrinolysis or disseminated intravascular coagulation (DIC) interfere with fibrin polymerization and prolong TT 7.

Other Causes

• Paraproteins: Monoclonal proteins in multiple myeloma or other plasma cell disorders can interfere with fibrin polymerization 7

• Acquired antibodies: Rare antibodies against fibrinogen or bovine thrombin (from reagent exposure) 7

• Liver failure: Impaired fibrinogen synthesis and quality 7

Clinical Algorithm for Interpretation

When TT is prolonged:

1. First, determine if patient is on anticoagulation:

   • If on dabigatran: Normal TT excludes drug effect; prolonged TT confirms presence but requires diluted thrombin time or ecarin clotting time for quantification 5, 9
   • If on UFH: Check for heparin contamination or therapeutic effect
   • If on LMWH or factor Xa inhibitors: TT should be normal; look elsewhere

2. If not on anticoagulants, check fibrinogen level:

   • Low (<150 mg/dL): Hypofibrinogenemia
   • Normal or high with prolonged TT: Consider dysfibrinogenemia—perform fibrinogen antigen assay 10
   • Very high (>500 mg/dL): May cause isolated TT prolongation without clinical significance 8

3. Assess for FDPs/DIC:

   • Check D-dimer, platelet count, PT/aPTT
   • If elevated FDPs with thrombocytopenia and prolonged PT/aPTT: Consider DIC

4. Consider paraproteinemia:

   • Check serum protein electrophoresis if monoclonal gammopathy suspected

Critical Pitfalls

• Do not use TT to quantify dabigatran levels—it's too sensitive. Use diluted thrombin time or ecarin-based assays instead 4, 5, 9.

• Do not rely on TT for factor Xa inhibitor detection—use anti-Xa assays calibrated to the specific drug 3.

• Heparin contamination from improper blood draw (drawing from heparinized line) will falsely prolong TT. Use Reptilase time to distinguish—Reptilase is unaffected by heparin but prolonged by fibrinogen disorders 10.

• Isolated TT prolongation with high fibrinogen is usually clinically insignificant and does not require intervention 8.